MARKET

ADMA

ADMA

ADMA Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.180
+0.140
+6.86%
After Hours: 2.150 -0.03 -1.38% 17:31 09/25 EDT
OPEN
2.080
PREV CLOSE
2.040
HIGH
2.200
LOW
2.020
VOLUME
1.86M
TURNOVER
--
52 WEEK HIGH
5.25
52 WEEK LOW
1.450
MARKET CAP
188.24M
P/E (TTM)
-2.5196
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Insider Buys ADMA Biologics Stock
A Form 4 filing filed with the SEC on Monday, September 14 showed that Demski Martha J bought 2,200 shares of ADMA Biologics Inc (NASDAQ:ADMA) at an average price of $2.29. The transaction moved the executive's stake in ADMA Biologics Inc. to 4,200 shares.
Benzinga · 09/14 15:56
ADMA Biologics to Participate in Morgan Stanley Virtual Healthcare Conference
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 09, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman
GlobeNewswire · 09/09 11:00
Do Institutions Own ADMA Biologics, Inc. (NASDAQ:ADMA) Shares?
If you want to know who really controls ADMA Biologics, Inc. (NASDAQ:ADMA), then you'll have to look at the makeup of...
Simply Wall St. · 09/08 11:41
Adma Biologics up 10% on launch of COVID-19 test
ADMA Biologics (ADMA) launches COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary immunoassay that detects SARS-CoV-2 neutralizing antibodies in plasma.It developed the test in collaboration with Leinco Technologies. Under the terms of
Seekingalpha · 09/03 12:25
The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2)
Benzinga · 09/03 11:55
ADMA Biologics Highlights Launch Of COVID-19 ImmunoRank Neutralization MICRO-ELISA For Use 'as an aid to identify individuals who produce an adaptive immune response to SARS-CoV-2'
  ImmunoRank Offers a Faster, Simpler, More Cost Effective Way to Identify High Titer Convalescent Plasma for Use in Both Treating COVID-19 Patients and for Creating COVID-19 Hyperimmune Globulins Proprietary
Benzinga · 09/03 11:02
ADMA Biologics Highlights Launch of COVID-19 ImmunoRank™ Neutralization MICRO-ELISA Assay to Detect SARS-CoV-2 Neutralizing Antibodies in Plasma
ImmunoRank Offers a Faster, Simpler, More Cost Effective Way to Identify High Titer Convalescent Plasma for Use in Both Treating COVID-19 Patients and for Creating COVID-19 Hyperimmune Globulins Proprietary Assay Developed in Collaboration with Leinco TechnologiesRAMSEY, N.J. and BOCA RATON, Fla., Sept
GlobeNewswire · 09/03 11:00
ADMA Biologics to Participate in Upcoming Investor Conferences
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 02, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman
GlobeNewswire · 09/02 11:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADMA. Analyze the recent business situations of ADMA Biologics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADMA stock price target is 9.86 with a high estimate of 15.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 131
Institutional Holdings: 57.02M
% Owned: 66.03%
Shares Outstanding: 86.35M
TypeInstitutionsShares
Increased
33
2.68M
New
36
416.56K
Decreased
26
2.17M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Steven Elms
President/Chief Executive Officer/Co-Founder/Director
Adam Grossman
Vice Chairman/Co-Founder/Director
Jerrold Grossman
Chief Financial Officer/Executive Vice President
Brian Lenz
Executive Vice President/Chief Scientific Officer
James Mond
Independent Director
Martha Demski
Independent Director
Bryant Fong
Independent Director
Lawrence Guiheen
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADMA
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ADMA Biologics Inc stock information, including NASDAQ:ADMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMA stock methods without spending real money on the virtual paper trading platform.